Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Respiratory Research

Fig. 2

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Fig. 2

Displays the four direct cost categories in relation to the total amount of direct costs. Patients with Alpha-1-antitrypsin deficiency (AATD) and augmentation therapy (AT) have lower inpatient but also higher outpatient costs, compared to the two other subgroups. Therefore, no significant differences could be detected between the three groups. However, AATD patients - especially non AT receiving AATD patients - tended to have lower direct costs

Back to article page